Latest News Archive

Please select Category, Year, and then Month to display items

The future of universities – Prof Burger part of DHET Expert Panel on University Fees

17 June 2025 | Story Lacea Loader | Photo Supplied

Prof Philippe Burger, Dean: Faculty of Economic and Management Sciences at the University of the Free State (UFS), has been appointed as a member of a team that will represent Universities South Africa (USAf) in a DHET Expert Panel on University Fees. The panel, which comprises representatives from USAf, the DHET, and NSFAS, focuses on the affordability of tuition fees and the future sustainability of the sector, looking at potential solutions for tuition fees beyond the 2025 academic year.

With more than 30 years of experience in higher education, mostly in management positions, Prof Burger understands the sector well. Combined with his expertise in macroeconomics, fiscal policy, and public sector economics and finance, he is uniquely positioned to make a significant contribution to this task team.

Universities matter

Despite the high national unemployment rate (32%), Prof Burger points out that unemployment is largely a problem of the unskilled. “The unemployment rate of people with university degrees is about 12%, much lower than the national average,” he notes. “South Africa has a large shortage of skilled labour, which it needs to grow the economy and improve lives.” He trusts that universities can fill this void, in addition to providing the thought leaders needed to take the country forward.

Although universities in South Africa are experiencing financial pressures, they continue to lift thousands of people to better lives each year. Universities make a profoundly positive contribution to the country and its population, and Prof Burger believes that once the public is fully aware of this, it will support broader discussions in favour of higher education.

The challenge

Universities face several cost pressures that are causing an increase in cost at a higher rate than consumer inflation, Prof Burger explains. “For instance, we buy equipment, software, and journal subscriptions that are all priced in US dollars. Affected by the exchange rate, these types of expenses have increased by much more than the price of consumer goods in South Africa over the past ten years.” According to Prof Burger, increased operational costs, coupled with constrained university income, necessitate a model that will provide universities with enough income to cover their costs while delivering quality education in the long run.

The solution

“There is an argument for universities to become more efficient, and there is certainly room for universities to look at their cost structures, but there is also a limit to what we can do,” Prof Burger says. “It is important to stress that we cannot talk about the sustainability of universities and not contextualise it within a framework that seeks to deliver quality learning, teaching, and research. In the absence of that quality, we will not be able to address the skills shortages and thought leadership that the country needs. And that is the sustainability we need to talk about – the sustainability of quality education and scholarship,” he concludes.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept